COV-ENT-1

COV-ENT-1 is an investigational small molecule candidate developed by Enterin for the treatment of COVID-19. As of early 2024, the drug is in the IND-enabling phase, with the company preparing for clinical trials. Enterin's research platform typically focuses on aminosterols, such as squalamine derivatives, which have demonstrated broad-spectrum antiviral activity in preclinical studies by modulating host cell membrane properties to inhibit viral entry and replication. While the specific molecular target for COV-ENT-1 has not been publicly disclosed, it represents the company's expansion into infectious disease therapeutics using its established enteric-focused platform.